Givinostat

Givinostat

Clinical data
Pregnancy category	—
Routes of administration	Oral
ATC code	none
Legal status
Legal status	US: Investigational New Drug EU: Orphan status for sJIA
Identifiers
IUPAC name {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate
CAS Number	497833-27-9 Y
PubChem CID	9804992
IUPHAR/BPS	7490
ChemSpider	7980752 N
UNII	5P60F84FBH
Chemical and physical data
Formula	C24H27N3O4
Molar mass	421.489 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(OCc2cc1ccc(cc1cc2)CN(CC)CC)Nc3ccc(cc3)C(=O)NO
InChI InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28) N Key:YALNUENQHAQXEA-UHFFFAOYSA-N N
NY (what is this?)

Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride.

Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas), and has been granted orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis and polycythaemia vera.

ITF2357 was discovered at of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005.

In clinical trials of givinostat as a salvage therapy for advanced Hodgkin's lymphoma, the most common adverse reactions were fatigue (seen in 50% of participants), mild diarrhea or abdominal pain (40% of participants), moderate thrombocytopenia (decreased platelet counts, seen in one third of patients), and mild leukopenia (a decrease in white blood cell levels, seen in 30% of patients). One-fifth of patients experienced prolongation of the QT interval, a measure of electrical conduction in the heart, severe enough to warrant temporary suspension of treatment.